Clinical Trials

Gynecologic Cancer Clinical Trials

Ovarian Cancer Clinical Trials

Ovarian Cancer Clinical Trials

Fate-NK100: NK Immunotherapy For Recurrent Ovarian Cancer Recruitment Locations:

Natural Killer (NK) cells, a cell of the immune system, are collected from a donor and delivered into the abdominal cavity of the patient. The NK cells work to target and kill tumor cells using the help of the body's immune system.

• University of Minnesota - M Health Gynecologic Cancer Cinic
ALTOR: ALT-803 Maintenance After First Line Chemotherapy Recruitment Locations:

ALT-803 activates the body's immune system to increase the time that it takes for cancer to recur. ALT-803 is given after initial chemotherapy.

• University of Minnesota - M Health Gynecologic Cancer Cinic
TRIO: Pembrolizumab and CC-486 For Recurrent Ovarian Cancer Recruitment Locations:

Immunotherapy drugs that target cancer cells and makes them more easily recognized and killed by the immune system. Pembrolizumab is given IV, and CC-486 is taken by mouth.

• University of Minnesota - M Health Gynecologic Cancer Clinic
NanoPac During 1st or 2nd Surgery for Ovarian Cancer Recruitment Locations:

During surgery, nano-particle chemotherapy is given directly in the abdominal cavity so that it can act directly at the site of the cancer and be more effective

• Univeristy of Minnesota - M Health Gynecologic Cancer Clinic

Endometrial Cancer Clinical Trials

Endometrial Cancer Clinical Trials

Exemestane: Exemestane Prior to Hysterectomy for Endometrial Disease Recruitment Locations:
Exemestane is taken by mouth for 3 weeks prior to surgical removal of the uterus (hysterectomy). The goal of reducing the ability of the tumor to grow. • University of Minnesota - M Health Gynecologic Cancer Clinic
GOG 286b: Adding Metformin to Chemotherapy in Recurrent or Advanced Endometrial Cancer Recruitment Locations:
In addition to standard chemotherapy, metformin is given to evaluate if it increases survival times when compared to chemotherapy alone. • Univeristy of Minnesota - M Health Gynecologic Cancer Clinic

Cervical Cancer Clinical Trials

Cervical Cancer Clinical Trials

Aim2Cerv: Advaxis For Maintenence of Advanced Cervical Cancer Recruitment Locations:
After chemoradiation for Cervical cancer, Advaxis is given as maintenence to increase the time that it takes for cancer to recur. • Univeristy of Minnesota - M Health Gynecologic Cancer Clinic
Why We Offer Clinical Trials
 
The health care providers in the Department of Obstetrics, Gynecology, and Women’s Health are committed to continually improving the standard of care in all aspects of women’s health. Clinical trials are critical for advancing the field of gynecologic cancer prevention and treatment. They also provide patients with the opportunity for improved health outcomes and a higher quality of life. We are proud to offer cutting edge, innovative treatments that patients often cannot get elsewhere. We encourage all our patients to ask their doctor if a clinical trial is right for them. Ask your health care provider about clinical trials available to you for your specific condition.  
 
Institutional Review Board
The Institutional Review Board (IRB) reviews research projects involving human participants, working with investigators to ensure adequate protection and informed, uncoerced consent. The IRB approves all research involving human subjects to ensure that it is conducted in accordance with all federal, institutional, and ethical guidelines. Clinical trials are necessary to advance the field of gynecologic cancer prevention and treatment while also providing women the opportunity to obtain improved health outcomes and a higher quality of life. 
 
For Frequently Asked Questions about Clinical Trials, see our Clinical Trials FAQ.
 

Find all Clinical Trials by Disease  

At the Masonic Cancer Center, University of Minnesota

Nationwide

Research Ethics at the University of Minnesota

We are committed to protecting research participants, upholding ethical standards, and improving our practice at every step of our work.